SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer

J. Randolph Hecht, Allen Cohn, Shaker Dakhil, Mansoor Saleh, Bilal Piperdi, Mika Cline-Burkhardt, Ying Tian, William Y. Go

Research output: Contribution to journalArticlepeer-review

93 Citations (Scopus)

Fingerprint

Dive into the research topics of 'SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer'. Together they form a unique fingerprint.

Neuroscience

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology